Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer

We are pleased to present the exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer. This series provides peer-to-peer physician perspectives on emerging data in the treatment of hormone receptor (HR)-positive/HER2-negative early to metastatic breast cancer.

All Episodes

• Part 1: Long-Term Outcomes of Adjuvant CDK4/6 Inhibitors in HR-Positive/HER2-Negative Early Breast Cancer
  Download Part 1 Transcript
• Part 2: Best Practices in Managing Early Breast Cancer With a High Risk of Recurrence
  Download Part 2 Transcript
• Part 3: Strategies for Staying on CDK4/6 Inhibitor Therapy
  Download Part 3 Transcript
• Part 4: First Results From VIKTORIA-1
  Download Part 4 Transcript
• Part 5: Results From TACTIVE-N
  Download Part 5 Transcript
• Part 6: Results From OptiTROP-Breast02
  Download Part 6 Transcript

Neil M. Iyengar, MD

Director, Survivorship Services, Winship Cancer Institute of Emory University
Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology
Associate Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, GA

Seth Wander, MD, PhD

Director, Precision Medicine, Termeer Center for Targeted Therapies
Director, Translational Research, Breast Oncology Program
Assistant Professor of Medicine, Harvard Medical School
Massachusetts General Hospital
Boston, MA